Definitive Contract 75N93024C00071

This is a $7,910,444.00 definitive cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to Integral Molecular Inc. The contract is for discovering and characterizing B cell epitopes against the viral pathogens Rift Valley Fever Virus, Crimean-Congo Hemorrhagic Fever Virus, and Enterovirus D68. The contract has a period of performance from September 16, 2024 to September 15, 2029 and was not set aside for any particular business type. Integral Molecular Inc. is a biotechnology company that specializes in innovative technologies and therapeutic antibodies for membrane protein targets, and has received multiple prime contracts and subcontracts from various federal agencies, including NIAID, the National Cancer Institute, and the Department of the Army, as well as several significant federal grant awards to support its research and development efforts.